Start Free Trial
GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-01 - Abaloparatid

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

February 28, 2028
Response Due
Active
Status

Opportunity Overview

This is an active government procurement opportunity, Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-01 - Abaloparatid, tracked by GlobalGov and issued by Health, Health, Health in Germany. It falls under the Pharmaceuticals category. Responses are due by February 28, 2028. It was published on January 28, 2026. Review the full details and track related opportunities below.

This is one of 1,481 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedJanuary 28, 2026
Response dueFebruary 28, 2028
StatusActive - open for responses
Official sourceView original notice
Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Dasatinib (ausschl. Wirkstärke 100 mg in der Normgröße N2 und N3, ATC L01EA02 f. d. Z. 01.11.24 - 31.10.26
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Pegfilgrastim (ATC: L03AA13)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 SGB V zu Wirkstoffen (Arzneimitteln) - VV 80
Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Sorafenib (L01EX02) im Rahmen eines sogenannten Open-House-Modells.
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Axitinib (ATC: L01EK01)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →